


Prior Authorization Review Panel
MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: AmeriHealth Caritas Pennsylvania & Keystone First		Submission Date: 6/1/25	
Policy Number: CCP.1415		Effective Date: 6/1/2019 Revision Date: 5/2025	
Policy Name: Corneal cross-linking			
Type of Submission:		Type of Policy:	
☐ New Policy		☒ Prior Authorization Policy	
☒ Revised Policy*		☐ Base Policy	
☐ Annual Review- no revisions		☐ Experimental/Investigational Policy	
		☐ Statewide PDL	
		☐ Other:	
*All revisions to the policy <u>must</u> be highlighted using track changes throughout the document. Please provide any clarifying information for the policy below:			
Name of Authorized Individual (Please type or print):		Signature of Authorized Individual:	
Manni Sethi, MD, MBA, CHCQM			

Corneal cross-linking

Clinical Policy ID: CCP.1415

Recent review date: 5/2025

Next review date: 9/2026

Policy contains: Collagen cross-linking; corneal ectasia; keratoconus; refractive surgery of cornea.

Keystone First- CHIP has developed clinical policies to assist with making coverage determinations. Keystone First- CHIP's clinical policies are based on guidelines from established industry sources, such as the Centers for Medicare & Medicaid Services (CMS), state regulatory agencies, the American Medical Association (AMA), medical specialty professional societies, and peer-reviewed professional literature. These clinical policies along with other sources, such as plan benefits and state and federal laws and regulatory requirements, including any state- or plan-specific definition of "medically necessary," and the specific facts of the particular situation are considered by Keystone First- CHIP, on a case by case basis, when making coverage determinations. In the event of conflict between this clinical policy and plan benefits and/or state or federal laws and/or regulatory requirements, the plan benefits and/or state and federal laws and/or regulatory requirements shall control. Keystone First- CHIP's clinical policies are for informational purposes only and not intended as medical advice or to direct treatment. Physicians and other health care providers are solely responsible for the treatment decisions for their patients. Keystone First- CHIP's clinical policies are reflective of evidence-based medicine at the time of review. As medical science evolves, Keystone First- CHIP will update its clinical policies as necessary. Keystone First- CHIP's clinical policies are not guarantees of payment.

Coverage policy

Corneal cross-linking using the photo enhancer riboflavin 5'-phosphate ophthalmic solution and ultraviolet A radiation is clinically proven and, therefore, may be medically necessary when the following criteria are met (Cortina, 2024; Jhanji, 2024; U.S. Food and Drug Administration, 2016).

- To treat documented progressive keratoconus or corneal ectasia after refractive surgery (Cortina, 2024).
- Progressive disease must be documented by serial measurements over time demonstrating worsening based on at least two of the following within the prior 12 months (Cortina, 2024; Jhanji, 2024)
 - Increase in maximum keratometry (Kmax) ≥ 1.0 Diopter (D);
 - Increase in posterior corneal elevation $\geq 15 \mu\text{m}$;
 - Reduction in minimum pachymetry $\geq 10 \mu\text{m}$;
 - Increase in manifest cylinder or spherical equivalent ≥ 1.0 D;
 - Steepening of the anterior corneal surface;
 - Steepening of the posterior corneal surface; or
 - Corneal thinning and/or an increase in the rate of corneal thickness change from the periphery to the thinnest point.
- For members under 18, topography every three to six months is recommended. Because of rapid disease velocity in this group, corneal cross-linking should be initiated promptly at the first objective sign of progression (Cortina, 2024; Jhanji, 2024)
- After conservative interventions have failed.

- When rapid progression is present, corneal cross-linking may be performed without prior failure of conservative interventions when the treating clinician determines that conservative measures are unlikely to stop disease progression (such as documented progression exceeding an increase in maximum keratometry of 1 diopter within six months).

For any determinations of medical necessity for medications, refer to the applicable state-approved pharmacy policy.

Limitations

Relative contraindications to corneal cross-linking are (Jhanji, 2024):

- Corneal stromal thickness below 400 μm .
- Prior herpes simplex virus keratitis.
- Significant central corneal stromal scarring that would impede treatment effectiveness or visualization.
- Severe, uncontrolled ocular-surface disease.
- Active autoimmune disorders known to affect corneal healing or cause corneal thinning .

Alternative covered services

- Routine patient evaluation and management by a network health care provider.
- Corrective glasses.
- Rigid and gas-permeable contact lenses.
- Intrastromal corneal ring segments.
- Keratorefractive surgery.
- Corneal transplant (keratoplasty).

Background

Keratoconus is a type of corneal ectasia that causes the normally round cornea to develop a cone-shaped bulge at its center, in areas where thinning is greatest. It causes blurry/distorted vision, sensitivity to light, and other vision problems. Other types of corneal ectasia include pellucid marginal degeneration, posterior keratoconus, and post-laser refractive surgery ectasia. Keratoconus is a rare ocular disease, affecting one in 2,000 Americans (National Organization for Rare Disorders, 2019).

The disorder often starts at puberty and is often observed in teenagers or young adults. Males, African Americans, and Latinos are at greater risk for developing the disease. Children with the disorder have a much greater proportion of severe (stage IV) cases than do adults. While no cause has been identified, environmental and genetic factors are suspected (National Organization for Rare Disorders, 2019).

Diagnosing the disease is feasible during a routine eye examination. Symptoms in the early stage include mild vision blurring, slightly distorted vision, sensitivity to light, and eye redness or swelling. Later stages include symptoms such as highly distorted nearsightedness and astigmatism, and inability to wear contact lenses due to the bulging cornea. Treatment of keratoconus often begins with corrective glasses or rigid and gas-permeable contact lenses to change the cornea back to its normal shape (Boyd, 2022).

Advanced treatments include intracorneal ring segments or a corneal transplant (keratoplasty) for failed response to conservative treatment. In children, treatment compliance is often poor. Corneal transplants have a higher risk of rejection and poor visual progress, and intracorneal ring segment implants are generally safe but have not been well studied in children (Olivo-Payne, 2019).

Corneal collagen cross-linking is a minimally invasive outpatient procedure that employs eye drops containing the photo enhancer riboflavin 5'-phosphate and local photo-polymerization using ultraviolet A light to strengthen the collagen bonds in the cornea. The standard Dresden protocol involves removing the outer layer of the corneal epithelium under topical anesthesia to allow penetration of riboflavin into the corneal tissue, followed by 30 minutes of eyedrop instillation using a slit lamp, followed by 30 minutes of ultraviolet A irradiation. Topical antibiotics and anti-inflammatory drops are usually prescribed after the procedure; in some cases, topical steroids may be necessary. One eye at a time is treated; repeat procedures may be necessary. Variations to the standard procedure include accelerated cross-linking (higher energy at a shorter duration), a transepithelial approach (epithelial-on), and a combination of cross-linking and either ring segment implantation or refractive surgery (Porter, 2022).

On April 15, 2016, the U.S. Food and Drug Administration approved corneal collagen cross-linking using Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution) and Photrexa (riboflavin 5'-phosphate ophthalmic solution), intended for use with ultraviolet A irradiation administered with the KXL® system. It is approved for patients with progressive keratoconus or corneal ectasia after refractive surgery using the Dresden protocol. Data submitted to support regulatory approval included participants between the ages of 14 and 65 years. Cross-linking is marketed in the United States as iLink™ corneal cross-linking (Glaucos Corp., San Clemente, California) and is the only approved corneal cross-linking system as of this writing (Kaufman, 2016).

Findings

Clinical Guidelines

Clinical guidelines establish corneal cross-linking (CXL) as a primary intervention for keratoconus and corneal ectasia, providing foundational recommendations for its application. The American Academy of Ophthalmology's 2022 Preferred Practice Pattern confirms that CXL reduces the risk of progressive ectasia in early-stage keratoconus, stabilizes the cornea without age restrictions, and mitigates post-keratorefractive surgery ectasia, recommending follow-up every three to six months, particularly for younger patients (American Academy of Ophthalmology, 2022). The 2023 Corneal Ectasia Preferred Practice Pattern reinforces CXL as the preferred treatment for progressive keratoconus, emphasizing early intervention to preserve visual acuity and listing contraindications such as corneal thickness below 400 µm, prior herpes simplex virus keratitis, corneal scarring, severe ocular surface disease, and autoimmune disorders associated with corneal thinning (Jhanji, 2024). It highlights that standard CXL effectively slows progression in pediatric patients, who face more aggressive disease.

European guidelines affirm CXL's safety and efficacy in improving visual acuity and topographic indices since its introduction in the 1990s (Alio, 2015; Andreanos, 2017). Additional guidance from the American Academy of

Ophthalmology in 2018 and 2021, along with a 2024 technology assessment of six randomized controlled trials (average 2.4 years follow-up), confirms CXL's ability to halt progression, with improvements in uncorrected distance visual acuity (UDVA) across all trials and corrected distance visual acuity (CDVA) in several, noting rare complications such as infectious keratitis (0.6%, 2/347 eyes) and CDVA loss of two or more lines (4.6%, 16/347 eyes) (American Academy of Ophthalmology, 2018; American Academy of Ophthalmology, 2021; Cortina, 2024).

Systematic Reviews

Systematic reviews synthesize qualitative evidence on CXL's outcomes, focusing on protocol comparisons and procedural variations. A 2024 review of 27 studies ($n = 1,399$) confirmed that both epithelium-off and epithelium-on CXL stabilize keratoconus progression, with epithelium-off yielding superior UDVA outcomes (Borchert, 2024). Another 2024 review of 29 studies ($n = 2,866$ eyes) found no significant outcome differences between pulsed and continuous CXL protocols, suggesting flexibility in energy delivery methods (Qureshi, 2025). These reviews highlight the consistency of CXL's stabilizing effects across diverse protocols, though variations in visual outcomes depend on procedural specifics.

Meta-Analyses

Meta-analyses provide quantitative evidence by pooling data to compare corneal cross-linking (CXL) protocols, with standard epithelium-off CXL often outperforming modified approaches. A 2017 analysis of 24 studies found standard CXL more effective than modified protocols, such as transepithelial or accelerated CXL, in delaying maximum keratometry (Kmax) deterioration ($P = .03$) (Liu, 2017). It also reported a significant reduction in spherical equivalent ($P < .00001$). A 2021 analysis of 12 studies ($n = 966$, mean age 23.88 years, SD 9.03) showed transepithelial CXL was inferior to epithelium-off CXL in Kmax change at 12 months ($P = .004$) and longest follow-up ($P < .001$) (Nath, 2021). Despite fewer complications ($P = .020$), transepithelial CXL had higher progression rates ($P = .022$), with similar UDVA ($P = .386$) and CDVA ($P = .732$) outcomes. A 2017 analysis of three randomized controlled trials ($n = 244$ eyes) confirmed standard CXL reduced Kmax more effectively than transepithelial CXL at 12 months (Li, 2017). Transepithelial CXL achieved greater CDVA improvement, but UDVA and safety profiles were similar. A 2019 analysis of seven studies ($n = 283$ eyes) reported accelerated CXL reduced average keratometry more than standard CXL ($P < .01$) (Jiang, 2019).

Other outcomes showed no significant differences. Another 2019 analysis of 22 studies ($n = 1,158$ eyes) showed standard CXL outperformed accelerated CXL in minimum keratometry ($P < .00001$) and demarcation line depth ($P < .00001$) (Shajari, 2019). Accelerated CXL was better for minimum corneal thickness ($P = .0005$). A 2018 analysis of 11 studies found epithelium-off and transepithelial CXL superior in Kmax reduction, while accelerated CXL improved central corneal thickness and endothelial cell density (Wen, 2018). A 2024 analysis of 14 randomized controlled trials ($n = 614$ eyes) found conventional CXL achieved greater Kmax flattening (SMD 0.302) than accelerated CXL (Yeh, 2025). Visual acuity and endothelial cell counts were similar. A 2023 analysis of four studies ($n = 329$ eyes) showed a 10-minute accelerated CXL protocol outperformed a 5-minute protocol in keratometry ($P < .00001$), corneal high-order aberration ($P = .0002$), and corneal coma ($P = .00001$) (Karam, 2023). A 2022 analysis of oxygen-enhanced epithelium-on CXL, analyzing five of six studies (n unspecified), reported a 1.2-diopter Kmax reduction (95% CI 0.2 to 2.3, $P = .02$) and CDVA improvement (0.08 logMAR, 95% CI 0.02 to 0.13, $P = .01$) after six months, with no serious adverse events (Borchert, 2022).

Meta-analyses also evaluate CXL combined with other procedures, demonstrating enhanced outcomes. A 2018 analysis of 17 studies found no differences in CDVA or cylindrical refractive error after 12 months among groups combining intracorneal ring segments (ICRS) and CXL on the same day, ICRS first, or CXL first (Hashemi, 2018). A 2019 analysis of 95 studies ($n = 4,560$) showed combined ICRS, CXL, and photorefractive keratectomy (PRK) outperformed ICRS alone in all measures except spherical equivalent correction, supporting its use in young patients (Benoist d'Azy, 2019). A 2025 analysis of eight non-randomized studies ($n = 731$ eyes) found combined customized PRK and CXL improved UDVA, CDVA, refractive cylinder, and higher-order aberrations compared to CXL alone, with similar progression rates over 6–44 months (Zhang, 2025).

Specific populations, such as pediatric patients and those with post-refractive surgery ectasia, benefit from CXL, as shown in targeted meta-analyses. A 2022 analysis in pediatric patients (37 studies, $n = 2,078$ eyes) calculated a 9.9% progression risk after standard CXL (95% CI 6.1% to 14.6%, $P < .0001$) based on Kmax, Kmean, or Ksteep increases ≥ 1.0 diopter (Achiron, 2022). Another 2022 pediatric analysis (11 studies, $n = 888$ eyes) found standard CXL improved CDVA more than accelerated CXL at 24 months ($P = .03$), with higher adverse effects but comparable other outcomes (Li, 2022). A 2024 analysis of 15 studies ($n = 421$) confirmed CXL's efficacy in post-refractive surgery ectasia, improving CDVA (SMD 0.33) and Kmax (SMD 0.15) (Amaral, 2024).

Other Evidence

Observational studies and other evidence provide critical long-term data on CXL's effectiveness and limitations. A 2022 retrospective case series ($n = 131$ eyes, 44 followed for 10 years) confirmed CXL slows or halts keratoconus progression and improves CDVA, but non-response rates increased from 16% at 5 years to 33% at 10 years, with risk factors including young age, high astigmatism (> 4.3 D), thin cornea (< 480 μm), poor initial CDVA (≥ 0.3 D), and atopic dermatitis (Seifert, 2022). A 2023 multinational registry study ($n = 976$ eyes at year 1, 162 at year 5) reported significant CDVA improvements from baseline at year 1 (3.7 logMAR letters, $P < .001$) and year 5 (6.9 logMAR letters, $P < .001$), with keratometry stabilizing after year 1, though 4.1% of patients had reduced CDVA and 5.9% to 7.5% showed poor keratometric responses (Ferdi, 2023). A 2021 Cochrane review reinforced CXL's efficacy and safety, aligning with prior findings (Ng, 2021).

A quality assessment of systematic reviews for corneal disease treatments validated the reliability of the synthesized evidence, supporting its use in policy development (Saldanha, 2019). Standard epithelium-off CXL, using the Dresden protocol, effectively halts mild to moderate keratoconus progression across age groups, improving CDVA, UDVA, and Kmax, particularly benefiting younger patients by delaying corneal transplantation. Modified protocols, such as transepithelial and accelerated CXL, show comparable visual outcomes but are less effective at halting progression, though transepithelial CXL reduces complications like postoperative pain, subepithelial haze, sterile infiltration, and infectious keratitis. Further research is needed to optimize protocols for pediatric patients, corneas thinner than 400 μm , and combinations with other surgical procedures.

In 2025, we reorganized the findings section and added five new systematic reviews and meta-analyses on corneal collagen crosslinking for ectasia after refractive surgery (Amaral, 2024), epithelium-on versus epithelium-off corneal collagen crosslinking (Borchert, 2024), pulsed corneal collagen crosslinking (Qureshi, 2025), accelerated versus conventional corneal collagen crosslinking (Yeh, 2025), and customized photorefractive keratectomy combined with corneal collagen crosslinking (Zhang, 2025)—as well as updated guidance from the American Academy of Ophthalmology (Cortina et al., 2024; Jhanji et al., 2024). Policy changes were made as the result of new guidelines.

References

On April 8, 2025, we searched PubMed and the databases of the Cochrane Library, the U.K. National Health Services Centre for Reviews and Dissemination, the Agency for Healthcare Research and Quality, and the Centers for Medicare & Medicaid Services. Search terms were “cross-linking,” “keratoconus,” “collagen,” and “riboflavin.” We included the best available evidence according to established evidence hierarchies (typically systematic reviews, meta-analyses, and full economic analyses, where available) and professional guidelines based on such evidence and clinical expertise.

Achiron A, El-Hadad O, Leadbetter D, et al. Progression of pediatric keratoconus after corneal cross-linking: A systematic review and pooled analysis. *Cornea*. 2022;41(7):874-878. Doi: 10.1097/ico.0000000000002808.

Alio JL, Saviz-Diez P, Vega-Estrada A, Pena-Garcia P. Keratoconus management guidelines. https://www.researchgate.net/publication/282904057_Keratoconus_Management_Guidelines . Published January, 2015.

Amaral DC, Menezes AHG, Lima LCV, et al. Corneal collagen crosslinking for ectasia after refractive surgery: a systematic review and meta-analysis. *Clin Ophthalmol*. 2024;18:865-879. Doi:10.2147/OPTH.S451232.

American Academy of Ophthalmology. Corneal ectasia preferred practice pattern. <https://www.aaopt.org/Assets/3806f63d-7e2d-4e1d-9803-2fed6ff01279/636777146051830000/corneal-ectasia-preferred-practice-pattern-2018-pdf>. Published 2018.

American Academy of Ophthalmology. Summary benchmarks for Preferred Practice Pattern® guidelines. <https://www.aaopt.org/Assets/0ee2e42f-34f4-4f64-a249-4def7deec3f6/638090379485430000/ppp-summary-benchmarks-22-full-set-pdf>. Published December 2022.

Andreanos KD, Hashemi K, Petrelli M, Droutas K, Georgalas I, Kymionis GD. Keratoconus treatment algorithm. *Ophthalmol Ther*. 2017;6(2):245-262. Doi: 10.1007/s40123-017-0099-1.

Benoist d'Azy C, Pereira B, Chiambaretta F, Dutheil F. Efficacy of different procedures of intra-corneal ring segment implantation in keratoconus: A systematic review and meta-analysis. *Transl Vis Sci Technol*. 2019;8(3):38. Doi: 10.1167/tvst.8.3.38.

Borchert GA, Watson SL, Kandel H. Oxygen in corneal collagen crosslinking to treat keratoconus: A systematic review and meta-analysis. *Asia Pac J Ophthalmol (Phila)*. 2022;11(5):453-459. Doi: 10.1097/apo.0000000000000555.

Borchert G, Kandel H, Watson SL. Epithelium-on versus epithelium-off corneal collagen crosslinking for keratoconus: a systematic review and meta-analysis. *Graefes Arch Clin Exp Ophthalmol*. 2024;262(6):1683-1692. Doi:10.1007/s00417-023-06287-8.

Boyd K. Keratoconus diagnosis and treatment. American Academy of Ophthalmology.

<https://www.aao.org/eye-health/diseases/keratoconus-diagnosis>. Last reviewed November 8, 2022.

Cortina MS, Greiner MA, Kuo AN, et al. Safety and efficacy of epithelium-off corneal collagen cross-linking for the treatment of corneal ectasia: a report by the American Academy of Ophthalmology. *Ophthalmology*. 2024;131(10):1234-1242. Doi:10.1016/j.ophtha.2024.05.006.

Ferdi AC, Kandel H, Nguyen V, et al. Five-year corneal cross-linking outcomes: A Save Sight Keratoconus registry study. *Clin Exp Ophthalmol*. 2023;51(1):9-18. Doi: 10.1111/ceo.14177.

Hashemi H, Alvani A, Seyedian MA, Yaseri M, Khabazhoob M, Esfandiari H. Appropriate sequence of combined intracorneal ring implantation and corneal collagen cross-linking in keratoconus: A systematic review and meta-analysis. *Cornea*. 2018;37(12):1601-1607. Doi: 10.1097/ICO.0000000000001740.

Jhanji V, Ahmad S, Amescua G, et al. Corneal Ectasia Preferred Practice Pattern. *Ophthalmology*. 2024;131(4):P205-P246. Doi:10.1016/j.ophtha.2023.12.038.

Jiang Y, Yang S, Li Y, Cui G, Lu TC. Accelerated versus conventional corneal collagen cross-linking in the treatment of keratoconus: A meta-analysis and review of the literature. *Interdiscip Sci*. 2019;11(2):282-286. Doi: 10.1007/s12539-019-00336-9.

Karam M, Alsaif A, Aldubaikhi A, et al. Accelerated corneal collagen cross-linking protocols for progressive keratoconus: Systematic review and meta-analysis. *Cornea*. 2023;42(2):252-260. Doi: 10.1097/ico.00000000000003124.

Kaufman MB. Pharmaceutical approval update. P.T. 2016; 41(8): 476, 478.

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4959615/>.

Li W, Wang B. Efficacy and safety of transepithelial corneal collagen crosslinking surgery versus standard corneal collagen crosslinking surgery for keratoconus: A meta-analysis of randomized controlled trials. *BMC Ophthalmol*. 2017;17(1):262. Doi: 10.1186/s12886-017-0657-2.

Li Y, Lu Y, Du K, et al. Comparison of efficacy and safety between standard, accelerated epithelium-off and transepithelial corneal collagen crosslinking in pediatric keratoconus: A meta-analysis. *Front Med (Lausanne)*. 2022;9:787167. Doi: 10.3389/fmed.2022.787167.

Liu Y, Liu Y, Zhang Y-N, et al. Systematic review and meta-analysis comparing modified cross-linking and standard cross-linking for progressive keratoconus. *Int J Ophthalmol*. 2017;10(9):1419-1429. Doi: 10.18240/ijo.2017.09.15.

Nath S, Shen C, Koziarz A, et al. Transepithelial versus epithelium-off corneal collagen cross-linking for corneal ectasia: A systematic review and meta-analysis. *Ophthalmology*. 2021;128(8):1150-1160. Doi: 10.1016/j.ophtha.2020.12.023.

National Organization for Rare Disorders. Rare disease database: Keratoconus. <https://rarediseases.org/rare-diseases/keratoconus/>. Last published 2019.

Ng SM, Ren M, Lindsley KB, Hawkins BS, Kuo IC. Transepithelial versus epithelium-off corneal crosslinking for progressive keratoconus. *Cochrane Database Syst Rev*. 2021;3(3):Cd013512. Doi: 10.1002/14651858.CD013512.pub2.

Olivo-Payne A, Abdala-Figuerola A, Hernandez-Bogantes E, Pedro-Aguilar L, Chan E, Godefrooji D. Optimal management of pediatric keratoconus: Challenges and solutions. *Clin Ophthalmol*. 2019;13:1183-1191. Doi: 10.2147/OPTH.S183347.

Porter D. Corneal cross-linking. <https://www.aao.org/eye-health/treatments/corneal-cross-linking-2>. Last reviewed January 6, 2022.

Qureshi M, Watson SL, Kandel H. Pulsed corneal crosslinking in the treatment of Keratoconus: a systematic review and meta-analysis. *Graefes Arch Clin Exp Ophthalmol*. 2025;263(3):589-601. Doi:10.1007/s00417-024-06622-7. Saldanha IJ, Lindsley KB, Lum F, Dickersin K, Li T. Reliability of the evidence addressing treatment of corneal diseases: A summary of systematic reviews. *JAMA Ophthalmol*. 2019;137(7):775-785. Doi: 10.1001/jamaophthalmol.2019.1063.

Seifert FK, Theuersbacher J, Schwabe D, Lamm O, Hillenkamp J, Kampik D. Long-term outcome of corneal collagen crosslinking with riboflavin and UV-a irradiation for keratoconus. *Curr Eye Res*. 2022;47(11):1472-1478. Doi: 10.1080/02713683.2022.2117383.

Shajari M, Kolb CM, Agha B, et al. Comparison of standard and accelerated corneal cross-linking for the treatment of keratoconus: A meta-analysis. *Acta Ophthalmol*. 2019;97(1):e22-e35. Doi: 10.1111/aos.13814.

U.S. Food and Drug Administration. Prescribing information: Photrexa viscous and Photrexa. https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/203324s000lbl.pdf . Published July 24, 2016.

Wen D, Li Q, Song B, et al. Comparison of standard versus accelerated corneal collagen cross-linking for keratoconus: A meta-analysis. *Invest Ophthalmol Vis Sci*. 2018;59(10):3920-3931. Doi: 10.1167/iovs.18-24656.

Yeh CY, Chen KC, Chen YJ, Cheng SF. Accelerated versus conventional corneal collagen cross-linking for keratoconus: A meta-analysis of randomized controlled trials. *Eur J Ophthalmol*. 2025;35(3):785-798. Doi:10.1177/11206721241298317.

Zhang H, Cantó-Cerdán M, Félix-Espinar B, Alió Del Barrio JL. Efficacy of customized photorefractive keratectomy with cross-linking versus cross-linking alone in progressive keratoconus: a systematic review and meta-analysis. *Am J Ophthalmol*. [Preprint] 2025. Doi:10.1016/j.ajo.2025.02.038.

Policy updates

4/2019: initial review date and clinical policy effective date: 6/2019

5/2020: Policy references updated.

5/2021: Policy references updated.

5/2022: Policy references updated. Limitations modified.

5/2023: Policy references updated.

5/2024: Policy references updated.

5/2025: Policy references updated.